Dianthus Therapeutics (DNTH) Misses Q4 EPS by 81c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
March 12, 2025 7:39 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)
The analyst comments "We are reiterating our Buy Rating on DNTH following their 4Q24 update. DNTH remains one of our favorite ideas for 2025 based on our broader view... More



